The new phase 3 clinical trial had included 667 adult patients in North America, Europe, and Latin America, who had received either 200 milligram pills of tedizolid for a week or 600 milligram pills twice as often for 10 days.
The drugs proved to show similar levels of effectiveness after three days, as well as after 11 days, according to the study that will be published in an issue of the Journal of the American Medical Association.
The side effects, most of which were mild or moderate, occurred in just over 40% of patients taking tedizolid, a 43% of those taking linezolid. The rates for serious side effects were low, and did not differ much between groups.
Dr. Phillippe Prokcimer, of Trius Therapeutics Inc., San Diego lead the study. The company is the creator of tedizolid and funded the project.
According to Green, the study suggests that tedizolid is a worthwhile alternative to older drugs. This holds true especially for MRSA, which is a growing problem, due to antibiotic resistance and the continued use of prolonged antibiotics.
Dr. Scott Gorenstein, who is an expert in wound healing therapies at Winthrop-University Hospital in Mineola, N.Y. Stated that it is important to find shorter alternatives to current treatment to reduce the cause of antibiotic-resistant complications.
About Skincare Paradise:
Skincare Paradise (http://www.skincareparadise.com/) provides quality products at affordable prices for all customers. Enjoy reading reviews on the highest quality product for your skin-care needs, and start saving on purchases today. Visit the Skin Care Paradise website for information on how to get rid of acne overnight.
This is a press release. Press release distribution and press release services by EmailWire.Com: http://www.emailwire.com/us-press-release-distribution.php.